Your vet is recommending switching your dog's medication to Trilotab®. Here's why...

Introducing Trilotab®

Improving quality of life for dogs with **Cushing's syndrome**

The flexibility to be precise



Trilotab® is the first chewable, flavoured and divisible tablet to treat dogs for Cushing's syndrome.

Shaping the future of animal health

Virbac

Trilotab®

Trilotab® is the first chewable, flavoured and divisible trilostane tablet for dogs and has been designed to simplify the treatment of Cushing's syndrome in dogs, making treatment easier for you and more enjoyable for your dog.



Tablets are easily divisible by 2 and 4 with "click tab" technology

- Enables flexible, precise and simpler dosing protocols for easy administration
- The tablets remain stable outside of the blister pack for up to four days to reduce wastage if you're not giving a full tablet

Chewable, chicken flavoured tablets

- Designed to make administering the treatment easier and more enjoyable
- Flavoured with hydrolysed chicken - this means that is it suitable for dogs to take that may be allergic to chicken

Trilotab® has demonstrated bioequivalence with the trilostane tablet that your dog is currently taking. This means that the two products are absorbed into the bloodstream at the same time and to the same extent. Therefore, your vet is able to move your dog from one product to the other without affecting their treatment.

For further information, please speak to your vet.

Trilotab® chewable tablets for dogs contain trilostane POM-V.

Advice on the use of this medicine should be sought from your veterinary surgeon. For more information, please refer to the SPC, datasheet or package leaflet.

Virbac Ltd, Woolpit Business Park, Windmill Avenue, Woolpit, Bury St Edmunds, Suffolk IP30 9UP. Tel: 01359 243243
Email: enquiries@virbac.co.uk Web: uk.virbac.com

Prescription decisions are for the person issuing the prescription alone.
Use medicines responsibly. www.noah.co.uk/responsible

Shaping the future of animal health

Virbac